An Open-Label Multi-Center Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 Alone or in Combination With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Cadonilimab (Primary) ; Lenvatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
- 23 Apr 2024 Status changed from active, no longer recruiting to completed.
- 17 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2021 New trial record